CoChat

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer

Open access
Tentler, John J., Nallapareddy, Sujatha, Tan, Aik Choon, Spreafico, Anna, Pitts, Todd M., Morelli, M. Pia, Selby, Heather M., Kachaeva, Maria I., Flanigan, Sara A., Kulikowski, Gillian N., Leong, Stephen, Arcaroli, John J., Messersmith, Wells A., Eckhardt, S. Gail · 2010 · Molecular Cancer Therapeutics
Cited by 77

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Mutant K-ras activity leads to the activation of the RAS/RAF/MEK/ERK pathway in approximately 44% of colorectal cancer (CRC) tumors. Accordingly, several inhibitors of the MEK pathway are under clinical evaluation in several malignancies including CRC. The aim of this study was to develop and characterize predictive biomarkers of response to the MEK1/2 inhibitor AZD6244 in CRC in order to maximize the clinical utility of this agent. Twenty-seven human CRC cell lines were exposed to AZD6244 and classified according to the IC50 value as sensitive (≤0.1 μmol/L) or resistant (>1 μmol/L). All cell lines were subjected to immunoblotting for effector proteins, K-ras/BRAF mutation status, and baseline gene array analysis. Further testing was done in cell line xenografts and K-ras mutant CRC human explants models to develop a predictive genomic classifier for AZD6244. The most sensitive and resistant cell lines were subjected to differential gene array and pathway analyses. Members of the Wnt signaling pathway were highly overexpressed in cell lines resistant to AZD6244 and seem to be functionally involved in mediating resistance by shRNA knockdown studies. Baseline gene array data from CRC cell lines and xenografts were used to develop a k-top scoring pair (k-TSP) classifier, which predicted with 71% accuracy which of a test set of patient-derived K-ras mutant CRC explants would respond to AZD6244, providing the basis for a patient-selective clinical trial. These results also indicate that resistance to AZD6244 may be mediated, in part, by the upregulation of the Wnt pathway, suggesting potential rational combination partners for AZD6244 in CRC. Mol Cancer Ther; 9(12); 3351–62. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-10-0376

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 77

Metadata

Authors
Tentler, J. J., Nallapareddy, S., Tan, A. C., Spreafico, A., Pitts, T. M., Morelli, M. P., Selby, H. M., Kachaeva, M. I., Flanigan, S. A., Kulikowski, G. N., Leong, S., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G.
Venue
Molecular Cancer Therapeutics
Published
2010-12-01
Volume
9
Issue
12
Pages
3351-3362
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2135707008
Cited by
77
References
9
FWCI
3.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0376
The paper
Tentler, J. J., Nallapareddy, S., Tan, A. C., Spreafico, A., Pitts, T. M., Morelli, M. P., Selby, H. M., Kachaeva, M. I., Flanigan, S. A., Kulikowski, G. N., Leong, S., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2010). Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.